StreetInsider.com News Articles

Scribe Therapeutics Inc (SCTX) PT Raised to $58 at Leerink

Tue, 25 Aug 2026 06:07:47 -0400

Leerink analyst David Risinger raised the price target on Scribe Therapeutics Inc (NASDAQ: SCTX) to $58.00 (from $37.00) while maintaining a Outperform rating.

Leerink Starts Scribe Therapeutics Inc (SCTX) at Outperform

Tue, 18 Aug 2026 06:07:37 -0400

Leerink analyst David Risinger initiates coverage on Scribe Therapeutics Inc (NASDAQ: SCTX) with a Outperform rating and a price target of $37.00.

For an analyst ratings summary and ratings history on Scribe Therapeutics Inc click here. For more ratings news on Scribe Therapeutics Inc click here.

Shares of Scribe Therapeutics Inc closed at $21.19 yesterday.

Wells Fargo Starts Scribe Therapeutics Inc (SCTX) at Overweight

Tue, 18 Aug 2026 04:56:41 -0400

Wells Fargo initiates coverage on Scribe Therapeutics Inc (NASDAQ: SCTX) with a Overweight rating and a price target of $60.00.

For an analyst ratings summary and ratings history on Scribe Therapeutics Inc click here. For more ratings news on Scribe Therapeutics Inc click here.

Shares of Scribe Therapeutics Inc closed at $21.19 yesterday.

Wells Fargo Starts Scribe Therapeutics Inc (SCTX) at Overweight

Tue, 18 Aug 2026 04:56:41 -0400

Wells Fargo initiates coverage on Scribe Therapeutics Inc (NASDAQ: SCTX) with a Overweight rating and a price target of $60.00.

For an analyst ratings summary and ratings history on Scribe Therapeutics Inc click here. For more ratings news on Scribe Therapeutics Inc click here.

Shares of Scribe Therapeutics Inc closed at $21.19 yesterday.

Guggenheim Starts Scribe Therapeutics Inc (SCTX) at Buy

Tue, 18 Aug 2026 03:44:28 -0400

Guggenheim analyst Debjit Chattopadhyay initiates coverage on Scribe Therapeutics Inc (NASDAQ: SCTX) with a Buy rating and a price target of $50.00.

The analyst comments: “Scribe has developed two proprietary CRISPR platforms: XE (X-Editor) and ELXR (Epigenetic Long-Term X-Repressor). Both platforms are engineered from CasX, a naturally occurring CRISPR nuclease first characterized in the lab of co-founder Jennifer Doudna. Cas X is evolutionarily distinct from Cas9, giving the company a differentiated intellectual property foundation in the crowded Cas9 patent landscape. CasX itself offers two intrinsic advantages over Cas9: ~30% smaller size enabling single-AAV delivery and broader in vivo flexibility, and a

Guggenheim Starts Scribe Therapeutics Inc (SCTX) at Buy

Tue, 18 Aug 2026 03:44:28 -0400

Guggenheim analyst Debjit Chattopadhyay initiates coverage on Scribe Therapeutics Inc (NASDAQ: SCTX) with a Buy rating and a price target of $50.00.

Goldman Sachs Starts Scribe Therapeutics Inc (SCTX) at Early-Stage Biotech

Tue, 18 Aug 2026 02:32:59 -0400

Goldman Sachs analyst Richard Law initiates coverage on Scribe Therapeutics Inc (NASDAQ: SCTX) with a Early-Stage Biotech rating.

The analyst comments: “We are initiating coverage on Scribe Therapeutics (SCTX) at Early-Stage Biotech (ESB). SCTX’s lead asset, STX-1150, is being developed as a novel epigenetic silencing therapy on the PCSK9 gene to treat elevated LDL-C without permanently modifying patients’ DNA nor subject to off-target editing risks. All approved PCSK9 products require chronic and life-long administration of daily, every 2 weeks, monthly, or every 6 months dosing. These products combined for ~$5B global sales in 2025 and are on track to achieve $6B+

Goldman Sachs Starts Scribe Therapeutics Inc (SCTX) at Early-Stage Biotech

Tue, 18 Aug 2026 02:32:59 -0400

Goldman Sachs analyst Richard Law initiates coverage on Scribe Therapeutics Inc (NASDAQ: SCTX) with a Early-Stage Biotech rating.

Scribe Therapeutics raises $155.51M in IPO on Nasdaq

Mon, 27 Jul 2026 16:05:08 -0400

Scribe Therapeutics Inc. (Nasdaq: SCTX), a clinical-stage biotechnology company, closed its initial public offering on July 27, 2026, raising approximately $155.51 million in aggregate gross proceeds before underwriting discounts and commissions.

The Alameda, California-based company sold 9,867,000 shares of common stock at $15.00 per share, including 1,287,000 additional shares issued following the full exercise of the underwriters' option. The company's shares began trading on the Nasdaq Global Market on July 24, 2026, under the ticker symbol "SCTX."

Alongside the IPO, Scribe Therapeutics closed a concurrent private placement of 500,000 shares to Sanofi at the IPO price of $15.00 per share. Those shares

Scribe Therapeutics raises $155.51M in IPO on Nasdaq

Mon, 27 Jul 2026 16:05:08 -0400

Alongside the IPO, Scribe Therapeutics closed a concurrent private placement of 500,000 shares to Sanofi at the IPO price of $15.00 per share. Those shares

Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement

Mon, 27 Jul 2026 16:05:00 -0400

ALAMEDA, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced the closing of its upsized initial public offering of 9,867,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 1,287,000 additional shares, at the initial public offering price of $15.00 per share. All of the shares were offered by Scribe Therapeutics. Scribe Therapeutics’ common stock began trading on

Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement

Mon, 27 Jul 2026 16:05:00 -0400

Scribe Therapeutics indicating open above $29, IPO priced at $15

Fri, 24 Jul 2026 11:05:44 -0400

Scribe Therapeutics indicating open above $29, IPO priced at $15

Scribe Therapeutics prices IPO at $15 per share on Nasdaq

Thu, 23 Jul 2026 21:08:46 -0400

Scribe Therapeutics Inc. (Nasdaq: SCTX), a clinical-stage biotechnology company, priced its initial public offering of 8,580,000 shares of common stock at $15.00 per share, the high end of its projected range, according to a press release statement.

The offering was upsized, with gross proceeds expected to reach $128.7 million before underwriting discounts, commissions, and other expenses. All shares are being sold by Scribe Therapeutics. The underwriters have been granted a 30-day option to purchase up to an additional 1,287,000 shares at the IPO price.